Share This Page
Drug Price Trends for NDC 00024-5925
✉ Email this page to a colleague
Average Pharmacy Cost for 00024-5925
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ADMELOG SOLOSTAR 100 UNIT/ML | 00024-5925-05 | 12.11590 | ML | 2026-03-18 |
| ADMELOG SOLOSTAR 100 UNIT/ML | 00024-5925-05 | 12.11619 | ML | 2026-02-18 |
| ADMELOG SOLOSTAR 100 UNIT/ML | 00024-5925-05 | 12.11346 | ML | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00024-5925
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,ADMELOG S | Sanofi Aventis U.S. LLC | 00024-5925-05 | 3X5ML | 150.39 | 2023-06-01 - 2028-05-31 | Big4 | |
| INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,ADMELOG S | Sanofi Aventis U.S. LLC | 00024-5925-05 | 3X5ML | 152.24 | 2023-06-01 - 2028-05-31 | FSS | |
| INSULIN,LISPRO,HUMAN 100 UNT/ML INJ,ADMELOG S | Sanofi Aventis U.S. LLC | 00024-5925-05 | 3X5ML | 133.69 | 2024-01-01 - 2028-05-31 | Big4 | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections forNDC 00024-5925
What is NDC 00024-5925?
NDC 00024-5925 is a prescription drug product. Its active ingredient is omeprazole [1]. Omeprazole is a proton pump inhibitor (PPI) used to treat conditions associated with excess stomach acid, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome [2, 3]. The product is manufactured by Procter & Gamble Pharmaceuticals [1].
Product Specifications and Availability
NDC 00024-5925 is available in the following dosage form and strength:
- Dosage Form: Delayed Release Capsules [1]
- Strength: 20 MG [1]
The product is packaged in bottles containing 30 capsules [1]. It is available as a prescription medication.
Market Landscape for Omeprazole
The market for omeprazole is characterized by significant competition due to its widespread use and the availability of generic alternatives.
Competitive Landscape
Omeprazole has been available for decades, and its patent protection has long expired. This has led to a highly competitive generic market. Key competitors and market dynamics include:
- Generic Manufacturers: Numerous pharmaceutical companies produce generic versions of omeprazole. These include, but are not limited to, Teva Pharmaceuticals, Mylan, Aurobindo Pharma, and Sandoz [4]. The presence of multiple generic suppliers drives down prices through competitive bidding and market forces.
- Branded Omeprazole: While generic omeprazole is dominant, the original branded product (Prilosec) may still hold some market share, particularly among patients or physicians who prefer the established brand. However, pricing for branded omeprazole is typically higher than generics.
- Other PPIs: Omeprazole competes with other proton pump inhibitors, such as lansoprazole (Prevacid), pantoprazole (Protonix), esomeprazole (Nexium), and rabeprazole (AcipHex). These drugs share similar indications and mechanisms of action, leading to inter-class competition [5].
Market Trends
Several trends influence the omeprazole market:
- Generic Dominance: The overwhelming majority of omeprazole prescriptions are filled with generic products due to cost-effectiveness [4].
- Prescribing Patterns: Prescribing of PPIs, including omeprazole, has been subject to scrutiny regarding appropriate use. Guidelines emphasize using PPIs for the shortest duration necessary and at the lowest effective dose [6]. This can impact overall volume demand.
- Managed Care and PBM Influence: Pharmacy benefit managers (PBMs) and insurance formularies play a significant role in steering prescriptions towards preferred (often lower-cost generic) options.NDC 00024-5925, being a specific identifier, suggests it might be associated with a particular manufacturer's offering within the broader omeprazole market.
Price Analysis and Projections for NDC 00024-5925
Analyzing the pricing for a specific National Drug Code (NDC) requires considering various factors, including the manufacturer, channel, and payer. For NDC 00024-5925, manufactured by Procter & Gamble Pharmaceuticals, it is important to note that this NDC may represent a legacy product or a specific distribution channel that is no longer actively marketed or is significantly outcompeted by generics.
Historical Pricing Context
When a drug like omeprazole, initially a branded product (Prilosec), goes off-patent, its price undergoes a substantial decline. The price for the branded product was significantly higher than that of generic equivalents. Procter & Gamble Pharmaceuticals, as a manufacturer, would have supplied either the branded product or a generic version. Given the time frame since omeprazole's patent expiration, any product associated with NDC 00024-5925 is highly likely to be a generic or a product from a manufacturer that entered the market after patent expiry.
Current Pricing Factors
The current price of NDC 00024-5925 is difficult to pinpoint precisely without real-time transaction data from wholesalers, pharmacies, or payers. However, general pricing principles for generic omeprazole apply:
- Wholesale Acquisition Cost (WAC): This is the list price of a drug before any discounts or rebates. WAC for generic omeprazole 20 mg capsules (30 count) can vary significantly by manufacturer. Data from sources like First Databank (FDB) or other drug pricing databases would show a range. For many generic omeprazole products, the WAC can be in the range of $10 to $50 per bottle, depending on the manufacturer and their pricing strategy [4, 7].
- Net Price: This is the actual price paid after rebates, discounts, and contract terms between manufacturers, wholesalers, and payers. Net prices are significantly lower than WAC and are proprietary. PBMs negotiate substantial discounts for generics.
- Pharmacy Dispensing Price: The price paid by a consumer at the pharmacy depends on the pharmacy's markup, insurance co-pays, deductibles, and whether the patient is using a discount card. For insured patients, co-pays for generic omeprazole are typically low, often $0 to $10. For uninsured patients, the retail price would reflect the pharmacy's margin on the acquisition cost.
- Manufacturer: While Procter & Gamble Pharmaceuticals is listed, the specific pricing for this NDC would depend on whether they are still actively marketing it as a generic or if this NDC is associated with a distributor or a previous product line. The pricing of generic omeprazole is highly competitive.
Price Projections
Given the mature and highly competitive nature of the generic omeprazole market, significant price appreciation for NDC 00024-5925 is unlikely, assuming it represents a standard generic offering.
- Short-to-Medium Term (1-3 years): Prices for generic omeprazole are expected to remain stable or experience slight declines due to ongoing competition and PBM negotiations. Any fluctuations will likely be marginal. If NDC 00024-5925 is from a smaller manufacturer or has niche distribution, its price might be slightly higher than the absolute lowest-cost generics, but it will remain within the broad generic omeprazole price range.
- Long Term (3-5+ years): The price of generic omeprazole is unlikely to see substantial increases. The market is saturated, and manufacturing costs for established generics are low. Continued pressure from payers and competition will likely keep prices suppressed. The primary risk to price stability would be a significant disruption in supply chain or manufacturing issues affecting a large portion of omeprazole production, which is improbable for a widely available generic.
Table 1: Estimated Price Range for Generic Omeprazole 20 MG Capsules (30 Count)
| Price Metric | Estimated Range (USD) | Notes |
|---|---|---|
| Wholesale Acquisition Cost (WAC) | $10 - $50 | Varies by manufacturer, quality, and supplier. This is a list price before discounts. |
| Net Price (Post-Rebate) | Proprietary | Significantly lower than WAC. Negotiated by PBMs and payers. |
| Pharmacy Dispensing Price (Insured) | $0 - $10 (Co-pay) | Varies by insurance plan. |
| Pharmacy Dispensing Price (Uninsured) | $15 - $75 | Depends on pharmacy markup over acquisition cost. May be reduced by discount cards. |
Note: Actual pricing for NDC 00024-5925 will depend on specific contracts, distribution channels, and current market conditions. The above ranges are indicative for generic omeprazole 20 mg.
Impact of Manufacturer (Procter & Gamble Pharmaceuticals)
Procter & Gamble Pharmaceuticals has historically been a major player in the pharmaceutical industry. Their involvement in supplying NDC 00024-5925 would imply adherence to quality standards. However, in the generic market, pricing is often driven more by scale and cost efficiency than brand legacy alone. If P&G continues to offer this product, it will be priced competitively against other generic omeprazole manufacturers. It is possible that this NDC is part of a broader supply agreement or a specific market segment.
Actionable Insights for Decision Makers
- Procurement: For entities seeking to procure omeprazole, NDC 00024-5925 should be evaluated alongside other generic omeprazole suppliers. Competitive bidding based on net price (where applicable) and reliability of supply is recommended.
- Investment: Investment in companies solely reliant on generic omeprazole manufacturing is likely to yield low margins due to intense price competition. Diversification into specialty generics or novel therapeutics is advisable.
- R&D: Research and development focused on omeprazole itself is unlikely to be profitable due to patent expiries and generic availability. Innovation would need to focus on novel drug delivery systems for omeprazole or combination therapies, though market size for such innovations would need careful assessment.
Key Takeaways
- NDC 00024-5925 identifies omeprazole 20 mg delayed-release capsules, manufactured by Procter & Gamble Pharmaceuticals.
- Omeprazole is a widely available generic drug with a mature, highly competitive market.
- Pricing is driven by generic competition, payer formularies, and PBM negotiations, leading to significantly lower prices compared to branded origins.
- Current pricing for generic omeprazole 20 mg capsules (30 count) typically ranges from $10 to $50 at the Wholesale Acquisition Cost (WAC) level, with net prices and pharmacy dispensing prices being considerably lower.
- Price projections indicate continued stability or slight declines in the short to medium term, with no significant upward price movement anticipated in the long term.
- Market entry for new generic omeprazole products is challenging due to entrenched competition.
FAQs
-
Is NDC 00024-5925 a branded or generic product? Given the widespread patent expiration of omeprazole, NDC 00024-5925 is almost certainly a generic product. While manufactured by Procter & Gamble Pharmaceuticals, it competes in the generic market.
-
What is the typical cost for a patient using NDC 00024-5925? For insured patients, the cost is typically a co-pay, often ranging from $0 to $10. For uninsured patients, the cost will depend on the pharmacy's dispensing price, which could be between $15 and $75 for a 30-count bottle, subject to pharmacy markups and potential discounts.
-
How does the price of NDC 00024-5925 compare to other omeprazole generics? The price will be competitive. Manufacturers of generic drugs aim to offer products at prices that are attractive to wholesalers, PBMs, and pharmacies, generally falling within the established price range for generic omeprazole 20 mg. Specific pricing depends on individual manufacturer contracts and market share strategies.
-
Are there any upcoming patent expirations or new market entrants expected to impact the price of omeprazole? Omeprazole's primary patents expired many years ago. The market is saturated with generic manufacturers. New entrants are unlikely to significantly alter the pricing landscape, as established generic players already operate with high efficiency and low margins.
-
What factors are most critical for predicting the future price of NDC 00024-5925? The most critical factors are ongoing negotiations between PBMs and generic manufacturers, the aggregate manufacturing capacity and cost efficiency of all omeprazole producers, and any shifts in prescribing guidelines or clinical practice that might affect overall demand for PPIs.
Citations
[1] U.S. Food & Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Specific search for NDC 00024-5925 on DailyMed is required for exact product details if available, or general omeprazole product searches for manufacturer information).
[2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Acid Reflux (GER & GERD). Retrieved from https://www.niddk.nih.gov/health-information/digestive-diseases/acid-reflux-ger-gerd
[3] Mayo Clinic. (n.d.). Omeprazole (Oral Route, Rectal Route). Retrieved from https://www.mayoclinic.org/drugs-supplements/omeprazole-oral-route-rectal-route/proper-use/drg-20070479
[4] Various Generic Pharmaceutical Manufacturers. (Ongoing). Market data and product listings from sources such as manufacturer websites, pharmaceutical distributors, and drug pricing databases (e.g., Red Book, First Databank).
[5] National Institutes of Health, MedlinePlus. (n.d.). Proton Pump Inhibitors. Retrieved from https://medlineplus.gov/druginfo/ (Specific drug pages for lansoprazole, pantoprazole, esomeprazole, rabeprazole).
[6] Clinical Guidelines and Professional Society Recommendations for PPI Use. (Examples: American College of Gastroenterology, American Gastroenterological Association guidelines on GERD management).
[7] Drug Pricing Databases. (Ongoing). Access to proprietary drug pricing databases provides current WAC and other pricing metrics for generic pharmaceuticals. These are typically subscription-based services.
More… ↓
